Cost-Effectiveness of a Multicancer Early Detection Test in the US美国多癌种早期检测测试的成本效益AMERICAN JOURNAL OF MANAGED CAREIF2.12024-12-131PRE
Predicting the Societal Value of Lecanemab in Early Alzheimer's Disease in Japan: A Patient-Level SimulationNEUROLOGY AND THERAPYIF4.82023-05-159OAAI
A Path to Improved Alzheimer's Care: Simulating Long-Term Health Outcomes of Lecanemab in Early Alzheimer's Disease from the CLARITY AD TrialNEUROLOGY AND THERAPYIF4.82023-04-0214OAAI
Estimated Societal Value of Lecanemab in Patients with Early Alzheimer's Disease Using Simulation ModelingNEUROLOGY AND THERAPYIF4.82023-03-166OAAI
The Potential Value-Based Price of a Multi-Cancer Early Detection Genomic Blood Test to Complement Current Single Cancer Screening in the USAPharmacoeconomicsIF4.62022-08-300OAAI
A Simulation Model to Evaluate the Potential Impact of Disease-Modifying Treatments on Burden of Illness in Alzheimer's DiseaseNEUROLOGY AND THERAPYIF4.82022-08-126OAAI
The Potential Economic Value of Lecanemab in Patients with Early Alzheimer's Disease Using Simulation ModelingNEUROLOGY AND THERAPYIF4.82022-06-2028OAAI
Long-Term Health Outcomes of Lecanemab in Patients with Early Alzheimer's Disease Using Simulation Modeling使用模拟建模的Lecanemab对早期阿尔茨海默病患者的长期健康结果NEUROLOGY AND THERAPYIF4.82022-04-2542OAAI
Efficiency Model of Cladribine Tablets Versus Infusion-Based Disease-Modifying Drugs for Patients with Relapsing-Remitting Multiple SclerosisADVANCES IN THERAPYIF42020-07-091PREAI
EVALUATION OF GLOBAL IMPROVEMENT AND LIFETIME COSTS OF TREATING TARDIVE DYSKINESIA SHOWS TREATMENT WITH VALBENAZINE DOMINATES DEUTETRABENAZINEVALUE IN HEALTHIF62019-05-011OAAI
EXPLORING THE EFFECTS OF SUBSEQUENT LIFE EXTENDING TREATMENTS ON CANCER TRIAL ENPOINTS USING CLINICAL TRIAL SIMULATIONVALUE IN HEALTHIF62018-10-010OAAI